Angeles Therapeutics

Angeles Therapeutics is a private, pre-clinical stage biotech focused on advancing next-generation CAR-T and CAR-NK cell therapies. Founded in 2020, the company is in the early stages of developing its technology platforms and asset portfolio, positioning itself in the competitive but high-potential cell and gene therapy sector. As a pre-revenue entity, its success will depend on advancing its science through preclinical validation, securing significant funding, and progressing assets into clinical trials. Key details regarding its pipeline, leadership team, and investors are not publicly disclosed on its minimal website.

Next-generation chimeric antigen receptor (CAR) platforms for engineering T-cells (CAR-T) and Natural Killer cells (CAR-NK). Aims to overcome limitations of current cell therapies like toxicity, antigen escape, and solid tumor penetration.

Highly competitive with numerous players like Allogene, Caribou Biosciences, Century Therapeutics, and large pharma (BMS, Gilead, Novartis) advancing next-gen CAR-T and allogeneic platforms. Angeles is a very early, private entrant with no disclosed data, placing it at a significant resource and timeline disadvantage.